AR038259A1 - Derivados sustituidos de aril-1,4-pirazina, composiciones farmaceuticas que los contienen, su uso para la elaboracion de medicamentos, articulo de fabricacion que los comprende, metodo para inhibir la union del crf al receptor de crf1, metodo para clasificar ligandos de receptores del crf y metodo p - Google Patents
Derivados sustituidos de aril-1,4-pirazina, composiciones farmaceuticas que los contienen, su uso para la elaboracion de medicamentos, articulo de fabricacion que los comprende, metodo para inhibir la union del crf al receptor de crf1, metodo para clasificar ligandos de receptores del crf y metodo pInfo
- Publication number
- AR038259A1 AR038259A1 ARP020104440A ARP020104440A AR038259A1 AR 038259 A1 AR038259 A1 AR 038259A1 AR P020104440 A ARP020104440 A AR P020104440A AR P020104440 A ARP020104440 A AR P020104440A AR 038259 A1 AR038259 A1 AR 038259A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocycloalkyl
- substituted
- heteroaryl
- pyrazine
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5751—Corticotropin releasing factor [CRF] (Urotensin)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S206/00—Special receptacle or package
- Y10S206/828—Medicinal content
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto que comprende un derivado sustituido de aril-1,4-pirazina de fórmula (1) o un estereoisómero de dicha fórmula, una sal farmacéuticamente aceptable de dicha fórmula, ó un profármaco de dicha fórmula, en donde en la fórmula (1): X se selecciona entre NR3R4, -OR3, -CR3R5R5, -C(O)R3,-S(O)mR3, -NR3C(O)R4, -NR3S(O)mR4, m es 0, 1 ó 2; Ar se selecciona entre arilo, arilo sustituido, heteroarilo, heteroarilo sustituido; R1, R2 y R5 se seleccionan independientemente entre halógeno, -NO2, -CN, -Ra, -ORa, -S(O)mRa, -NRaRa, -C(O)NRaRa, -C(S)NRaRa-S(O)mNRaRa,-NRaS(O)mRa, -NRaC(O)ORa, -OC(O)NRaRa, -NRaC(O)NRaRa, -NRaC(S)NRaRa, -C(O)ORa, -C(S)ORa, y -OC(O)ORa; R3 y R4 se seleccionan independientemente entre Ra, heterocicloalquilo, heterocicloalquilo sustituido, heteroarilo sustituido, arilo sustituido, aril-cicloalquilo, aril-cicloalquilo sustituido, heteroaril-cicloalquilo, heteroaril-cicloalquilo sustituido, aril-heterocicloalquilo, aril-heterocicloalquilo sustituido, heteroaril-heterocicloalquilo, ó heteroaril-heterocicloalquilo sustituido siempre que por lo menos uno entre R3 ó R4 sea heteroarilo, heteroarilo sustituido, aril-cicloalquilo, aril-cicloalquilo sustituido, heteroaril-cicloalquilo, heteroaril-cicloalquilo sustituido, aril-heterocicloalquilo, aril-heterocicloalquilo sustituido, heteroaril-heterocicloalquilo, heteroaril-heterocicloalquilo sustituido, heterocicloalquilo ó heterocicloalquilo sustituido; cada Ra se selecciona entre H, alquilo, cicloalquilo, haloalquilo, arilo, heteroarilo, ó heterocicloalquilo opcionalmente sustituido con 1 a 5 de Rt, -ORt, -S(O)mRt, NRtRt, oxo(=O), tiona (=S), fenilo, heteroarilo, ó heterocicloalquilo en donde fenilo, heteroarilo, y heterocicloalquilo están opcionalmente sustituidos con 1 a 5 grupos seleccionados independientemente entre Rt; y cada Rt se selecciona entre H, halógeno, -NO2, -NH2, -OH, -SH, -CN, -C(O)NH2, -C(O)-NH alquilo, -C(O)N alquilalquilo, -O alquilo, NH alquilo, Nalquilalquilo, -S(O)malquilo, SO2NH2, SO2NHalquilo y SO2N alquilalquilo, alquilo, cicloalquilo, haloalquilo, fenilo, bencilo, heteroarilo, ó heterocicloalquilo en donde fenilo, bencil-heteroarilo y heterocicloalquilo pueden estar opcionalmente sustituidos con alquilo o halógeno, siempre que el compuesto no sea: 2,5-dimetil-3-(2,4-diclorofenil)-6-[(1-metilpiperidin-4-il)oxi]pirazina; 2,5-dimetil-3-(2,4-diclorofenil)-6-(tetrahidrofuran-3-il)oxi]pirazina; 2,5-dimetil-3-(2,4-diclorofenil)-6-(tetrahidro-2H-piran-4-iloxi)pirazina, 2,5-dimetil-3-(2,4-diclorofenil)-6-[(1-metilpiperidin-3-il)oxi]pirazina, 2,5-dimetil-3-(2,4-diclorofenil)-6-[1-etilpiperdin-3-il)oxi]pirazina, 2,5-dimetil-3-(2,4-diclorofenil)-6-(1-piperidin-4-il)oxi]pirazina, 2,5-dimetil-3-(2,4-diclorofenil)-6-piperidin-3-il)oxi]pirazina, 2,5-dimetil-3-(2,4-diclorofenil)-6-[(1-etilpirrolidin-3-il)oxi]pirazina, 2,5-dimetil-3-(2,4-diclorofenil)-6-[(1-metilpirrolidin-3-il)oxi]pirazina, 2,5-dimetil-3-(2,4-diclorofenil)-6-[(pirrolidin-3-il)oxi]pirazina, 2,5-dimetil-3-(2,4-diclorofenil)-6-[(piridin-4-il)oxi]pirazina. También se dan a conocer composiciones farmacéuticas que los contienen, su uso para la elaboración de medicamentos, artículo de fabricación que los comprende, método para inhibir la unión del CRF al receptor CRF1, método para clasificar ligandos de receptores del CRF y método para detectar receptores del CRF en tejidos. Estos compuestos son útiles para la elaboración de medicamentos útiles para el tratamiento de trastornos de ansiedad, depresión y trastornos relacionados con el estrés.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33205201P | 2001-11-21 | 2001-11-21 | |
US35854602P | 2002-02-21 | 2002-02-21 | |
US38828502P | 2002-06-13 | 2002-06-13 | |
US41037802P | 2002-09-13 | 2002-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR038259A1 true AR038259A1 (es) | 2005-01-12 |
Family
ID=42777082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104440A AR038259A1 (es) | 2001-11-21 | 2002-11-19 | Derivados sustituidos de aril-1,4-pirazina, composiciones farmaceuticas que los contienen, su uso para la elaboracion de medicamentos, articulo de fabricacion que los comprende, metodo para inhibir la union del crf al receptor de crf1, metodo para clasificar ligandos de receptores del crf y metodo p |
Country Status (4)
Country | Link |
---|---|
US (2) | US6992087B2 (es) |
AR (1) | AR038259A1 (es) |
MY (1) | MY130489A (es) |
TW (1) | TWI292758B (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704995B2 (en) * | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
US7592340B2 (en) * | 2003-12-04 | 2009-09-22 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
US20060211710A1 (en) * | 2005-03-17 | 2006-09-21 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
DK1959955T3 (da) * | 2005-12-05 | 2011-02-07 | Pfizer Prod Inc | Fremgangsmåde til behandling af abnorm cellevækst |
CA2632283C (en) * | 2005-12-05 | 2011-06-21 | Pfizer Products Inc. | Polymorphs of a c-met/hgfr inhibitor |
US9216963B2 (en) * | 2006-06-22 | 2015-12-22 | Medibeacon Inc. | Pyrazine derivatives with extended conjugation and methods of using the same in optical applications |
JP5702293B2 (ja) | 2008-11-10 | 2015-04-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
NZ593969A (en) * | 2008-12-19 | 2013-11-29 | Vertex Pharma | Pyrazine derivatives useful as inhibitors of atr kinase |
JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
WO2011143425A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
CN102947272A (zh) | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的2-氨基吡啶衍生物 |
SG185524A1 (en) | 2010-05-12 | 2012-12-28 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2013000103A (es) | 2010-06-23 | 2013-06-13 | Vertex Pharma | Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art. |
EP2694498B1 (en) | 2011-04-05 | 2016-03-30 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
PL2940017T3 (pl) | 2011-09-30 | 2020-03-31 | Vertex Pharmaceuticals Incorporated | Sposób wytwarzania związków przydatnych jako inhibitory kinezy atr |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
CA2850564A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP3733185B1 (en) | 2011-09-30 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Treating non-small cell lung cancer with atr inhibitors |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776419B1 (en) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
CA2869309C (en) | 2012-04-05 | 2021-02-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
WO2014055756A1 (en) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
PT3486245T (pt) | 2012-12-07 | 2021-07-30 | Vertex Pharma | 2-amino-n-(piperidin-1-il-piridin-3- il)pirazolo[1,5alfa]pirimidina-3-carboxamida como inibidor da quinase atr |
EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
EP3077397B1 (en) | 2013-12-06 | 2019-09-18 | Vertex Pharmaceuticals Inc. | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
KR101859315B1 (ko) * | 2014-05-30 | 2018-05-18 | 제이에프이 스틸 가부시키가이샤 | 열연 강판의 제조 방법, 강판 절단 위치 설정 장치, 강판 절단 위치 설정 방법, 및 강판 제조 방법 |
SG10201902206QA (en) | 2014-06-05 | 2019-04-29 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
KR20170016498A (ko) | 2014-06-17 | 2017-02-13 | 버텍스 파마슈티칼스 인코포레이티드 | Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법 |
WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
US10793561B2 (en) | 2017-07-18 | 2020-10-06 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
MX2020000690A (es) | 2017-07-18 | 2020-07-29 | Nuvation Bio Inc | Compuestos heterociclicos como antagonistas de adenosina. |
WO2019213386A1 (en) * | 2018-05-04 | 2019-11-07 | New Mexico Tech University Research Park Corporation | Proteasome inhibitors |
AU2020207952A1 (en) * | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
MX2021008650A (es) | 2019-01-18 | 2021-11-03 | Nuvation Bio Inc | Compuestos heterociclicos como antagonistas de adenosina. |
WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
KR20210135240A (ko) * | 2019-02-05 | 2021-11-12 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997035901A1 (en) | 1996-03-27 | 1997-10-02 | Akzo Nobel N.V. | Alkyd resins having a low dynamic viscosity for use in high-solids coatings |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU721952B2 (en) | 1996-04-03 | 2000-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5872136A (en) | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
CA2250936A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
JP2001507699A (ja) | 1996-12-30 | 2001-06-12 | メルク エンド カンパニー インコーポレーテッド | ファルネシル蛋白トランスフェラーゼ阻害薬 |
MA26473A1 (fr) | 1997-03-01 | 2004-12-20 | Glaxo Group Ltd | Composes pharmacologiquement actifs. |
PA8467401A1 (es) | 1998-02-17 | 2000-09-29 | Pfizer Prod Inc | Procedimiento para tratar la insuficiencia cardiaca |
AU783915B2 (en) | 2000-02-16 | 2005-12-22 | Neurogen Corporation | Substituted arylpyrazines |
-
2002
- 2002-11-15 US US10/298,193 patent/US6992087B2/en not_active Expired - Fee Related
- 2002-11-19 AR ARP020104440A patent/AR038259A1/es unknown
- 2002-11-20 MY MYPI20024336A patent/MY130489A/en unknown
- 2002-11-21 TW TW091133953A patent/TWI292758B/zh not_active IP Right Cessation
-
2004
- 2004-05-12 US US10/844,004 patent/US7041672B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MY130489A (en) | 2007-06-29 |
US20050049257A1 (en) | 2005-03-03 |
US6992087B2 (en) | 2006-01-31 |
TW200301699A (en) | 2003-07-16 |
TWI292758B (en) | 2008-01-21 |
US20030144297A1 (en) | 2003-07-31 |
US7041672B2 (en) | 2006-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR038259A1 (es) | Derivados sustituidos de aril-1,4-pirazina, composiciones farmaceuticas que los contienen, su uso para la elaboracion de medicamentos, articulo de fabricacion que los comprende, metodo para inhibir la union del crf al receptor de crf1, metodo para clasificar ligandos de receptores del crf y metodo p | |
BR0313297A (pt) | 6-alcóxi-pirido-pirimidinas como inibidores de p-38 map cinase | |
AR040286A1 (es) | Proceso para la preparacion de pirimidinas sustituidas | |
CN101155807A (zh) | 具有tie2(tek)抑制活性的化合物 | |
KR950031113A (ko) | 약리학적 활성이 있는 피롤로피리미딘 유도체 | |
CA2455181A1 (en) | Benzimidazo[4,5-f]isoquinolinone derivatives | |
BR9812944A (pt) | Inibidores bicìclicos da cinase | |
AR037731A1 (es) | Uso de ureas de benzotiazoles | |
AR006108A1 (es) | Pirimido[5,4-d]pirimidinas, sus sales fisiologicamente compatibles, un procedimiento para su preparacion, su empleo para la preparacion de composiciones farmaceuticas, y las composiciones farmaceuticas que las contienen | |
BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
AR043199A1 (es) | Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes | |
ECSP055747A (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos | |
WO2002088080A2 (en) | Dual inhibitors of pde 7 and pde 4 | |
SE0302487D0 (sv) | Novel compounds | |
AR057817A1 (es) | Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas | |
RU2007123360A (ru) | Пирролопиразины и пиразолопиразины, полезные в качестве ингибиторов протеинкиназ | |
ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
BR9812527A (pt) | Inibidores de benzenossulfonamida de pde-iv e seu uso terapêutico | |
AR054000A1 (es) | Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo | |
AR016428A1 (es) | Compuestos de 1,3,8-triaza-espiro[4,5]decan-4-ona, un proceso para su preparacion, medicamentos que comprenden dichos compuestos y el uso de dichos compuestos para la manufactura de un medicamento | |
CA2553704A1 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
AR048501A1 (es) | Compuesto de benzoazabicicloheptano dimerico, composicion farmaceutica que lo comprende y su uso para prepararla | |
AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. | |
AR056418A1 (es) | Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento | |
AR037611A1 (es) | Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |